SOURCES SOUGHT
A -- OPTIMIZATION AND DEVELOPMENT OF AUTOMATED SYNTHESIS PRCEDURES FOR THE PRODCUTION OF FES
- Notice Date
- 1/9/2004
- Notice Type
- Sources Sought
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- 24XS036
- Response Due
- 1/23/2004
- Archive Date
- 2/7/2004
- Point of Contact
- Shannon Jackson, Contract Specialist, Phone 301-846-1520, Fax 301-846-5414, - Lori Brooks, Secretary II, Phone (301) 846 - 1718, Fax (301) 846 - 5414,
- E-Mail Address
-
sjackson@mail.ncifcrf.gov, lbrooks@mail.ncifcrf.gov
- Description
- SAIC-Frederick, Inc, under its OTS contract with the NCI is interested in issuing a Blanket Ordering Agreement (BOA), IDIQ contract or other long term contractual instrument for the optimization and development of automated synthesis procedures for the production of imaging agents of interest to the Cancer Imaging Program of the National Cancer Institute. The contractor will be required to develop automated synthesis methods, write Standard Operating Procedures (SOPs), compile necessary information and documents, and write and develop the Investigators Brochures required for eventual IND submissions. The optimization and development of automated synthesis procedures for the production of the imaging agents of interest will be based on the GE TracerLab FX automated synthesis module/system. The current agents of interest are: -Estrogen receptor status in patients with breast cancer using the PET tracer [18F]-16-alpha-Fluoroestradiol (FES) -Tumor hypoxia using the PET agent [18F]-Fluoromisonidazole (FMISO) -Malignant tumor proliferation using the PET tracer 3?-Deoxy-3?-[18F]-Fluorothymidine (FLT) -Tumor apoptosis using the imaging agent 18F-Annexin (FAN) Any interested parties must have specific published experience ? including the radio-chemistry, synthetic methodology, basic science use, and preliminary human use ? and particular expertise in PET radiochemistry of new and novel PET imaging agents used in cancer investigations. In addition, interested parties must also have sufficient experience and knowledge to automate the synthetic processes with the GE TracerLab synthesis module, as these processes will serve as the backbone, and are key to the success, of all of the Cancer Imaging Program phase I and phase II clinical trials using PET agents. The complete institutional infrastructure must exist to perform this work. A 5 year, cost reimbursement, contract/BOA is anticipated. Interested parties must fax or email their contact information, as well as a brief summary of their pertinent experience, to the following: Email: Palmerk@ncifcrf.gov; fax: (301) 228-4037. If you have any questions contact Ken Palmer at (301) 228-4021.
- Place of Performance
- Address: N/A
- Record
- SN00501215-W 20040111/040109211743 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |